Clinical Trial

Orexin Receptor Antagonism and Sleep in Stimulant Use Disorder

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine the effects of suvorexant (SUVO), on sleep, stress, and drug craving during early abstinence from stimulants and to determine the effects of treatment (SUVO vs. treatment as usual (TAU)) on post-treatment (Days 13-30) residential program length of stay (LOS) and completion rate.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-05-30; most recent amendment 2025-09-03.
Status change: Not Yet Recruiting → Recruiting 2024-07-31
Trial Details
NCT Number NCT06444256
Lead Sponsor The University of Texas Health Science Center, Houston
Conditions Stimulant Use Disorder
Enrollment 20 participants
Start Date 2024-07-25
Primary Completion 2027-01-30 (estimated)
Study Completion 2027-01-30 (estimated)
Updated on ClinicalTrials.gov 2025-09-05